CPT® Code 81420

1. Indications

The fetal chromosomal aneuploidy genomic sequence analysis panel (CPT® Code 81420) is indicated under specific circumstances that may suggest the presence of chromosomal abnormalities in the fetus. These indications include:

• Maternal Age Over 35 Years - Advanced maternal age is a well-known risk factor for chromosomal abnormalities, making this test particularly relevant for women in this age group.
• Elevated Maternal Free Beta-hCG Level - An increased level of this hormone in maternal blood can indicate a higher risk of fetal aneuploidy.
• Abnormal Fetal Ultrasound Findings - Ultrasound results showing increased nuchal translucency may suggest potential trisomy 21, 18, or 13, warranting further investigation through this test.
• Maternal History of Prior Pregnancy with Fetal Aneuploidy - A previous pregnancy affected by chromosomal abnormalities increases the likelihood of recurrence, making this test a valuable tool for risk assessment.

2. Procedure

The procedure for conducting the fetal chromosomal aneuploidy genomic sequence analysis involves several key steps:

• Step 1: Blood Sample Collection - A blood sample is obtained from the mother through a venipuncture, which is a standard procedure for drawing blood. This sample is crucial as it contains circulating cell-free fetal DNA that will be analyzed.
• Step 2: Laboratory Analysis - The collected whole blood is sent to a laboratory where it undergoes testing for fetal DNA fragments. This is achieved using targeted sequencing techniques, which allow for the identification of specific chromosomal abnormalities.
• Step 3: Data Interpretation - The laboratory analyzes the results to detect any chromosomal aneuploidies, specifically focusing on chromosomes 13, 18, and 21. The findings are then compiled into a report for the healthcare provider.
• Step 4: Follow-Up Recommendations - If the test results are positive for any chromosomal abnormalities, the healthcare provider may recommend further genetic testing options, such as chorionic villus sampling or amniocentesis, to confirm the findings and assess the health of the fetus.

3. Post-Procedure

After the fetal chromosomal aneuploidy genomic sequence analysis is completed, the healthcare provider will review the results with the patient. If the results indicate a potential chromosomal abnormality, the provider will discuss the implications and may recommend additional testing to confirm the diagnosis. It is important for the patient to understand the results and the next steps, which may include genetic counseling to explore the options available based on the findings. Recovery from the blood draw is typically quick, with no significant downtime required. Patients are advised to monitor for any unusual symptoms following the venipuncture, although complications are rare.